Carey K Anders

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Breast cancer before age 40 years
    Carey K Anders
    University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 36:237-49. 2009
  2. pmc Stratifying triple-negative breast cancer: which definition(s) to use?
    Barbara Adamo
    Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Drive, CB 7305, Chapel Hill, NC 27599 7305, USA
    Breast Cancer Res 13:105. 2011
  3. pmc Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
  4. pmc αB-crystallin: a novel regulator of breast cancer metastasis to the brain
    Dmitry Malin
    Authors Affiliations Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health Department of Chemical and Biological Engineering, University of Wisconsin, Madison, Wisconsin Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Breast Cancer Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Barcelona, Spain Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois Department of Pathology and Lab Medicine, Carolinas Medical Center, Charlotte, North Carolina Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota and Department of Medicine and Department of Pathology, Duke University Medical Center, Durham, North Carolina
    Clin Cancer Res 20:56-67. 2014
  5. pmc Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
    Emily O Jenkins
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Oncologist 19:1076-83. 2014
  6. pmc Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer
    Carey K Anders
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 8:e61359. 2013
  7. pmc Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer
    Carey K Anders
    University of North Carolina, Chapel Hill, 27517, USA
    Clin Cancer Res 16:4702-10. 2010
  8. pmc Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer
    Olga Karginova
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Department of Medicine, The University of Chicago, Chicago, Illinois
    Mol Cancer Ther 14:920-30. 2015
  9. pmc A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience
    Megan J McKee
    Atlanta Cancer Care, Atlanta, Georgia, USA University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA Department of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 21:16-20. 2016
  10. ncbi request reprint Breast cancer in adolescents and young adults: a review with a focus on biology
    Jill R Tichy
    From the aUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and bDana Farber Cancer Institute, Boston, Massachusetts
    J Natl Compr Canc Netw 11:1060-9. 2013

Collaborators

Detail Information

Publications15

  1. pmc Breast cancer before age 40 years
    Carey K Anders
    University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 36:237-49. 2009
    ....
  2. pmc Stratifying triple-negative breast cancer: which definition(s) to use?
    Barbara Adamo
    Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Drive, CB 7305, Chapel Hill, NC 27599 7305, USA
    Breast Cancer Res 13:105. 2011
    ..To place results into context, we review several definitions available under the TNBC umbrella that may stratify TNBC into clinically relevant subgroups...
  3. pmc Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
    ..Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR) and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative BCBMs...
  4. pmc αB-crystallin: a novel regulator of breast cancer metastasis to the brain
    Dmitry Malin
    Authors Affiliations Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health Department of Chemical and Biological Engineering, University of Wisconsin, Madison, Wisconsin Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Breast Cancer Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Barcelona, Spain Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois Department of Pathology and Lab Medicine, Carolinas Medical Center, Charlotte, North Carolina Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota and Department of Medicine and Department of Pathology, Duke University Medical Center, Durham, North Carolina
    Clin Cancer Res 20:56-67. 2014
    ..We investigated the potential role of αB-crystallin in brain metastasis in TNBCs...
  5. pmc Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
    Emily O Jenkins
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Oncologist 19:1076-83. 2014
    ..Few data exist on the frequency of molecular subtypes in older women. Here, we characterize the incidence and outcomes of BC patients by molecular subtypes and age...
  6. pmc Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer
    Carey K Anders
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 8:e61359. 2013
    ..We compared pharmacokinetics (PK) and efficacy of PEGylated liposomal doxorubicin (PLD) with non-liposomal doxorubicin (NonL-doxo) in an intracranial model of BC...
  7. pmc Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer
    Carey K Anders
    University of North Carolina, Chapel Hill, 27517, USA
    Clin Cancer Res 16:4702-10. 2010
    ....
  8. pmc Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer
    Olga Karginova
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Department of Medicine, The University of Chicago, Chicago, Illinois
    Mol Cancer Ther 14:920-30. 2015
    ..Combination therapy represents a potential promising treatment strategy for patients with TNBC brain metastases warranting further clinical investigation...
  9. pmc A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience
    Megan J McKee
    Atlanta Cancer Care, Atlanta, Georgia, USA University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA Department of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 21:16-20. 2016
    ..We describe organization and design of the clinic as well as characteristics, treatments, and outcomes of the patients seen in its first 3 years...
  10. ncbi request reprint Breast cancer in adolescents and young adults: a review with a focus on biology
    Jill R Tichy
    From the aUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and bDana Farber Cancer Institute, Boston, Massachusetts
    J Natl Compr Canc Netw 11:1060-9. 2013
    ..This article addresses the epidemiology, genetics, and management of breast cancer in AYA women and highlights unique medical issues important to this population. ..
  11. pmc Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate
    Raeshell S Sweeting
    Division of Surgical Oncology, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, North Carolina, USA
    Am Surg 77:850-5. 2011
    ..This suggests that neoadjuvant chemotherapy may identify young women for whom BCT may have an acceptable risk of LRR...
  12. pmc The management of early-stage and metastatic triple-negative breast cancer: a review
    Carey K Anders
    Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA
    Hematol Oncol Clin North Am 27:737-49, viii. 2013
    ..The general principles guiding the use of chemotherapy and radiation therapy do not differ dramatically between early-stage TNBC and non-TNBC. ..
  13. pmc Triple-negative breast cancer: an update on neoadjuvant clinical trials
    Keith D Amos
    Division of Surgical Oncology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Int J Breast Cancer 2012:385978. 2012
    ..In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC...
  14. pmc The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases
    Carey K Anders
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Cancer 117:1602-11. 2011
    ..In a single-institution cohort study, the authors attempted to determine whether the inferior outcome noted with TNBC brain metastases is more reflective of a higher risk population or the subtype itself...
  15. pmc Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer
    Carey K Anders
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, 27599, USA
    Clin Breast Cancer 9:S73-81. 2009
    ..Finally, the positive association between triple-negative breast cancer and BRCA mutations makes inhibition of poly(adenosine diphosphate-ribose) polymerase-1 an attractive therapeutic strategy that is in active study...